S2P:FRA
Simcere Pharmaceutical Group Ltd
€1.05
arrow_downward
-1.87%(-0.020) 1D
Jun 3, 10:00:00 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for S2P...
Open
€1.05
High
€1.05
Low
€1.05
Mkt. cap
25.49B
Avg. vol.
3.00
Volume
0.00
52-wk high
€1.60
52-wk low
€1.05
No. of employees
7K
Open
€1.05
High
€1.05
Low
€1.05
Mkt. cap
25.49B
Avg. vol.
3.00
Volume
0.00
52-wk high
€1.60
52-wk low
€1.05
No. of employees
7K
News stories
From sources across the web
TradingView
·
27 minutes ago
Radian Announces Inducement Grants To Incoming Chief Executive Officer Under NYSE Rule
Investor's Business Daily
·
1 hour ago
Futures: Two AI Giants Skid; SpaceX IPO Price Target Set
Caledonian Record
·
1 hour ago
American Resources Receives Nasdaq Notice Regarding Late Form 10-Q Filing Following Transformational Restructuring
Fox Business
·
16 minutes ago
Morningstar says SpaceX worth less than half its IPO target
Profile
Simcere Pharmaceutical Group or Simcere Pharmaceutical is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration to manufacture and sell over 210 other products. Wikipedia
About Simcere Pharmaceutical Group Ltd
CEORen Jinsheng
Employees7.04K
Founded1995
HeadquartersNanjing, Jiangsu, China
SectorPharmaceutical industry
Websitesimcere.com
AI content may include mistakes. Learn more